-+ 0.00%
-+ 0.00%
-+ 0.00%

Ernexa Therapeutics authorizes 1-for-10 to 1-for-25 reverse stock split to meet Nasdaq bid rule

PUBT·04/13/2026 13:29:04
Listen to the news
Ernexa Therapeutics authorizes 1-for-10 to 1-for-25 reverse stock split to meet Nasdaq bid rule
  • Ernexa board adopted reverse stock split resolutions March 26, 2026.
  • Majority shareholder written consent received March 27, 2026, covering 15,552,343 shares, or 53.3% voting power.
  • Action authorizes board to set reverse split ratio within 1-for-10 to 1-for-25.
  • Move targets Nasdaq minimum bid price rule requiring $1 per share for continued listing.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ernexa Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-016310), on April 13, 2026, and is solely responsible for the information contained therein.